Fulcrum Therapeutics Income Statement (2019-2025) | FULC

Income Statement Jun2019 Sep2019 Dec2019 Mar2020 Jun2020 Sep2020 Dec2020 Mar2021 Jun2021 Sep2021 Dec2021 Mar2022 Jun2022 Sep2022 Dec2022 Mar2023 Jun2023 Sep2023 Dec2023 Mar2024 Jun2024 Sep2024 Dec2024 Mar2025 Jun2025 Sep2025
Revenue & cost
Revenue 0.75M2.00M1.85M4.22M4.79M4.38M4.93M5.06M2.59M1.88M1.18M0.69M0.29M0.88M0.76M0.87M80.00M
Operating items
Research & Development 14.48M12.78M15.64M16.14M16.33M17.38M17.08M18.91M17.83M25.02M15.37M18.57M16.71M17.85M18.24M19.00M19.77M17.26M14.64M11.71M13.40M14.30M
Selling, General & Administrative 5.06M5.15M5.31M5.87M5.50M6.68M8.63M9.71M10.76M11.10M9.71M10.13M11.52M10.32M9.96M9.86M10.06M10.25M8.42M7.72M7.00M7.56M
Restructuring Costs 0.47M-0.04M2.06M
Operating Expenses 19.55M17.92M20.95M22.01M21.83M24.06M25.70M28.62M28.59M36.12M25.54M28.66M28.23M28.17M28.20M28.86M29.83M27.51M25.13M19.43M20.40M21.86M
Operating Income -18.80M-15.92M-19.10M-17.79M-17.04M-19.68M-20.77M-23.56M-26.00M-34.23M-24.36M-27.97M-27.94M-27.29M-27.44M-27.99M-29.83M52.49M-25.13M-19.43M-20.40M-21.86M
EBIT -18.80M-15.92M-19.10M-17.79M-17.04M-19.68M-20.77M-23.56M-26.00M-34.23M-24.36M-27.97M-27.94M-27.29M-27.44M-27.99M-29.83M52.49M-25.13M-19.43M-20.40M-21.86M
Non-operating items
Interest & Investment Income 0.34M0.24M0.14M0.07M0.04M0.03M0.05M0.07M0.07M0.17M0.62M1.84M3.16M3.51M3.42M3.24M2.96M2.92M3.43M2.86M2.75M2.26M
Net income details
EBT -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.66M-19.59M
Profit After Tax -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.66M-19.59M
Income from Continuing Operations -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.66M-19.59M
Consolidated Net Income -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.66M-19.59M
Income towards Parent Company -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-23.78M-24.02M-24.76M-26.87M55.41M-21.70M-16.57M-17.66M-19.59M
Net Income towards Common Stockholders -18.45M-15.69M-18.96M-17.72M-17.00M-19.65M-20.72M-23.48M-25.93M-34.07M-23.74M-26.14M-24.78M-24.78M-24.02M-24.76M-26.87M-26.87M-21.70M-16.57M-17.66M-19.59M
Additional items
EPS (Basic) -0.81-0.66-0.70-0.63-0.54-0.60-0.57-0.58-0.64-0.83-0.51-0.47-0.41-0.38-0.39-0.40-0.430.89-0.35-0.27-0.28-0.31
EPS (Weighted Average and Diluted) -698.90-0.54-0.57-0.58-0.64-0.83-0.51-0.47-0.41-0.38-0.39-0.40-0.430.87-0.35-0.27-0.28-0.31
Shares Outstanding (Weighted Average) 23.34M23.34M23.34M23.36M27.45M27.45M27.46M32.67M32.68M32.71M40.55M40.64M40.85M41.01M52.05M61.76M61.76M61.82M61.82M61.94M62.15M62.40M53.94M53.98M53.98M54.09M
Shares Outstanding (Diluted Average) 0.03M0.03M0.04M0.04M0.04M0.04M0.05M0.04M0.06M61.79M61.82M0.06M61.98M63.68M63.69M0.06M62.48M62.54M62.60M
EBITDA -18.50M-15.55M-19.01M-17.75M-17.00M-19.65M-20.79M-23.79M-26.62M-34.05M-24.36M-27.97M-27.94M-27.29M-27.44M-27.99M-29.83M52.49M-20.95M-16.82M-20.40M-19.44M